Gefapixant
Feb 06, 2023
Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?
Patients who are battling this crippling ailment find that chronic refractory cough (CRC), also known as refractory chronic cough (RCC) or unexplained chronic cough (UCC), proves to be a major burden. DelveInsight’s analysis estimates that in the US, there were approximately 12.7 million 12-month prevalent episodes...
Read More...
Aug 10, 2020
Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference
Merck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is presenting key posters and...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
